Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin

Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin

One combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently licensed in the USA (M-M-R II; Merck, USA) and another has been developed (Priorix™ [MMR-RIT, GSK, Belgium]). In this follow-up study, children from USA or Puerto Rico, who had received one dose of M-M-R...

Full description

Bibliographic Details
Main Authors: Andrea A. Berry, Remon Abu-Elyazeed, Clemente Diaz-Perez, Maurice A. Mufson, Christopher J. Harrison, Michael Leonardi, Jerry D. Twiggs, Christopher Peltier, Stanley Grogg, Antonio Carbayo, Steven Shapiro, Michael Povey, Carmen Baccarini, Bruce L. Innis, Ouzama Henry
Format: Article
Language:English
Published: Taylor & Francis Group 2017-07-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
antibody persistence
mmr vaccine
measles
mumps
priorix
rubella
Online Access:http://dx.doi.org/10.1080/21645515.2017.1309486

Internet

http://dx.doi.org/10.1080/21645515.2017.1309486

Similar Items